206 related articles for article (PubMed ID: 27454469)
1. Potential of Translationally Controlled Tumor Protein-Derived Protein Transduction Domains as Antigen Carriers for Nasal Vaccine Delivery.
Bae HD; Lee J; Jin XH; Lee K
Mol Pharm; 2016 Sep; 13(9):3196-205. PubMed ID: 27454469
[TBL] [Abstract][Full Text] [Related]
2. On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs.
Bae HD; Lee K
J Control Release; 2013 Sep; 170(3):358-64. PubMed ID: 23791976
[TBL] [Abstract][Full Text] [Related]
3. Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin.
Bae HD; Lee J; Jun KY; Kwon Y; Lee K
Drug Deliv; 2018 Nov; 25(1):1025-1032. PubMed ID: 29688087
[TBL] [Abstract][Full Text] [Related]
4. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
Slütter B; Jiskoot W
J Control Release; 2010 Nov; 148(1):117-121. PubMed ID: 20600405
[TBL] [Abstract][Full Text] [Related]
5. Modified translationally controlled tumor protein-derived protein transduction domain enhances nasal delivery of exendin-4 as shown with insulin.
Bae HD; Kim M; Lee J; Lee K
Drug Deliv; 2018 Nov; 25(1):1579-1584. PubMed ID: 30044154
[TBL] [Abstract][Full Text] [Related]
6. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
7. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
[TBL] [Abstract][Full Text] [Related]
8. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
9. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
Slütter B; Bal SM; Que I; Kaijzel E; Löwik C; Bouwstra J; Jiskoot W
Mol Pharm; 2010 Dec; 7(6):2207-15. PubMed ID: 21043518
[TBL] [Abstract][Full Text] [Related]
10. Cell-Penetrating Peptide Penetratin as a Potential Tool for Developing Effective Nasal Vaccination Systems.
Muto K; Kamei N; Yoshida M; Takayama K; Takeda-Morishita M
J Pharm Sci; 2016 Jun; 105(6):2014-2017. PubMed ID: 27155764
[TBL] [Abstract][Full Text] [Related]
11. Transduction of translationally controlled tumor protein employing TCTP-derived protein transduction domain.
Maeng J; Kim HY; Shin DH; Lee K
Anal Biochem; 2013 Apr; 435(1):47-53. PubMed ID: 23256924
[TBL] [Abstract][Full Text] [Related]
12. Protein transduction domain of translationally controlled tumor protein: characterization and application in drug delivery.
Maeng J; Lee K
Drug Deliv; 2022 Dec; 29(1):3009-3021. PubMed ID: 36104954
[TBL] [Abstract][Full Text] [Related]
13. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
14. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice.
Huang CF; Wang CC; Wu TC; Chu CH; Peng HJ
Ann Allergy Asthma Immunol; 2007 Nov; 99(5):443-52. PubMed ID: 18051215
[TBL] [Abstract][Full Text] [Related]
15. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens.
Duverger A; Jackson RJ; van Ginkel FW; Fischer R; Tafaro A; Leppla SH; Fujihashi K; Kiyono H; McGhee JR; Boyaka PN
J Immunol; 2006 Feb; 176(3):1776-83. PubMed ID: 16424208
[TBL] [Abstract][Full Text] [Related]
16. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
17. Mucosal vaccination using claudin-4-targeting.
Kakutani H; Kondoh M; Fukasaka M; Suzuki H; Hamakubo T; Yagi K
Biomaterials; 2010 Jul; 31(20):5463-71. PubMed ID: 20398936
[TBL] [Abstract][Full Text] [Related]
18. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.
Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H
Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512
[TBL] [Abstract][Full Text] [Related]
19. A protein transduction domain located at the NH2-terminus of human translationally controlled tumor protein for delivery of active molecules to cells.
Kim M; Kim M; Kim HY; Kim S; Jung J; Maeng J; Chang J; Lee K
Biomaterials; 2011 Jan; 32(1):222-30. PubMed ID: 20863558
[TBL] [Abstract][Full Text] [Related]
20. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
